Get the Stockscreener App
11.18
1.06%
-0.125
Prothena Corporation Plc stock is traded at $11.18, with a volume of 173.76K.
It is down -1.06% in the last 24 hours and up +8.86% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$11.30
Open:
$11.18
24h Volume:
173.76K
Relative Volume:
0.27
Market Cap:
$602.09M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-11.18
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+4.00%
1M Performance:
+8.86%
6M Performance:
+120.95%
1Y Performance:
-19.74%
1-Day Range:
$11.01
$11.48
1-Week Range:
$10.14
$11.57
52-Week Range:
$4.32
$17.66
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
11.19 | 600.74M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.67 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.40 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
457.35 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
898.01 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.49 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Will Prothena Corporation plc stock outperform international peersTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Prothena (NASDAQ:PRTA) Stock Price Up 7.4%Here's Why - MarketBeat
Are Smart Investors Making the Right Decision? Prothena Corporation plc (PRTA) - Setenews
Citizens Jmp Forecasts Strong Price Appreciation for Prothena (NASDAQ:PRTA) Stock - MarketBeat
Prothena (NASDAQ:PRTA) Price Target Raised to $19.00 at Citizens Jmp - Defense World
Prothena stock price target raised to $19 from $11 at Citizens - Investing.com Nigeria
Prothena stock price target raised to $19 from $11 at Citizens By Investing.com - Investing.com South Africa
Citizens Raises Price Target for Prothena Corp (PRTA) to $19.00 - GuruFocus
Prothena Corporation plc Stock Analysis and ForecastFundamental Stock Analysis & Double Digit Portfolio Growth - earlytimes.in
Why (PRTA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Aug PreEarnings: Why Prothena Corporation plc stock remains undervaluedRecession Risk & Target Return Focused Stock Picks - BỘ NỘI VỤ
What analysts say about Prothena Corporation plc stockInterest Rate Changes & Small Budget Capital Gains - earlytimes.in
Prothena (NASDAQ:PRTA) Upgraded at Chardan Capital - Defense World
How Prothena Corporation plc stock performs during Fed tightening cyclesJuly 2025 Reactions & Low Risk Entry Point Guides - newser.com
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - BioSpace
Will Prothena Corporation plc stock see PE expansionQuarterly Growth Report & Free Reliable Trade Execution Plans - newser.com
Prothena Shareholders Approve Capital Reduction Proposal - TipRanks
Prothena presents TDP-43 CYTOPE data showing promise for ALS treatment - Investing.com Australia
Prothena (PRTA) Highlights Breakthrough in Drug Delivery at Neur - GuruFocus
Prothena announces poster presentation on its TDP-43 Cytope® program at neuroscience 2025 - MarketScreener
Prothena Announces Poster Presentation On Its TDP-43 Cytope® Program At Neuroscience 2025 - TradingView
What’s the recovery path for long term holders of Prothena Corporation plcPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Will Prothena Corporation plc stock see insider buyingWeekly Trend Summary & Community Shared Stock Ideas - newser.com
Understanding Momentum Shifts in (PRTA) - news.stocktradersdaily.com
Will Prothena Corporation plc stock maintain momentum in 2025 - newser.com
Market reaction to Prothena Corporation plc’s recent newsWeekly Market Summary & Fast Entry High Yield Tips - newser.com
What MACD and RSI say about Prothena Corporation plcTrade Performance Summary & Community Verified Watchlist Alerts - newser.com
Can Prism Finance Limited Outperform Index Funds Over the Next 5 YearsEnergy Sector Updates & Outstanding Investment Returns - earlytimes.in
What drives Prothena Corporation plc stock pricePrice Action Analysis & Low Risk Investment Plans - earlytimes.in
Can Asarfi Hospital Limited Reach New Highs in YEAR Resistance Levels ReviewedInsider Trading Activity & Test Our Stock Screener — Free Forever - earlytimes.in
Should you hold or exit Prothena Corporation plc nowJuly 2025 Pullbacks & Capital Protection Trading Alerts - newser.com
Will Prothena Corporation plc stock reach all time highs in 2025Weekly Trend Summary & AI Powered Market Trend Analysis - newser.com
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prothena Corporation Plc Stock (PRTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
| EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
| SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
| SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
| SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
| SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
0.84%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):